Live Breaking News & Updates on Mounjaro

Stay informed with the latest breaking news from Mounjaro on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mounjaro and stay connected to the pulse of your community

Wegovy Shortage: Some Weight Loss Drugs Are Back In Stock, FDA Says

Booming demand for weight loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound has vastly outpaced Novo Nordisk and Eli Lilly’s ability to produce the medication and supplies of smaller doses have been limited for months.

Novo-wegovy , Eli-lilly-mounjaro , Eli-lilly-zepbound , Companies-working-on-competitor-weight-loss-drugs , Drug-administration , Novo-nordisk , Big-pharma , Wegovy-rivals , Wegovy , Ozempic , Mounjaro , Zepbound

Demand for weight-loss drug drives Eli Lilly to raise 2024 sales forecast by US$2-billion

Eli Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro

United-states , North-carolina , Germany , Denmark , Danish , Lilly-zepbound , David-ricks , Eli-lilly , Novo-nordisk , Nexus-pharmaceuticals , Walmart , Reuters

A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1

The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the consensus estimates.

Eli-lilly , Health-care , Trefis-high-quality-portfolio , Mounjaro , Zepbound , S-ampp-500 , Lly-stock , Lly-revenue ,

Move over, Humira, there's a new mega-blockbuster in town

There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster drug. Not anymore. That title now belongs to Novo Nordisk A/S’ semaglutide, approved as Ozempic in 2017 to treat diabetes and as Wegovy in 2021 to help with weight loss.

Novo-nordisk , Merck-co , Novo-nordiska-s , Semaglutide , Ozempic , Wegovy , Humira , Adalimumab , Keytruda , Merck-amp-co-inc- , Pembrolizumab , Abbvie-inc-

Wisconsin family-owned manufacturer acquired by pharma giant Eli Lily

The FDA-approved facility located in Pleasant Prairie is a leading sterile manufacturer in the pharmaceutical industry.

Pleasant-prairie , Wisconsin , United-states , Illinois , Milwaukee-county , Lincolnshire , Oak-creek , Taylor-swift , Usman-ahmed , Eli-lilly , Edgardo-hernandez , Mariam-darsot

New Diabetes Guidelines For Ozempic And Other GLP-1 Use

The body for the first time is calling for GLP-1s as a treatment for Type 2 diabetes, but the medications are in short supply.

North-carolina , United-states , Duke-university , Germany , German , American , Americans , Eli-lilly , Fatima-zyed , American-college-of-physicians , American-diabetes-association , Duke-university-division

Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss Drugs

Ozempic maker Novo Nordisk and Mounjaro maker Eli Lilly dominate the lucrative weight loss drug market with Wegovy and Zepbound, but companies are racing to compete in one of the most lucrative markets in the history of the pharmaceutical industry.

San-francisco , California , United-states , China , Germany , United-kingdom , Denmark , Switzerland , Swiss , Chinese , Danish , German

Obesity drug India: Lilly could launch obesity drug in India next year, CEO says

Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments.

Denmark , Telangana , Andhra-pradesh , India , United-states , Danish , David-ricks , Eli-lilly , Reuters , Novo-nordisk , Obesity-drug-india , Obesity-drug

Viking's Weight Loss Drug Challenges Ozempic-Maker Novo Nordisk And Eli Lilly — What To Know About The Latest Obesity Treatment

Viking Therapeutics’ stock more than doubled on Tuesday following the release of trials results suggesting its injectable obesity treatment outperforms industry leaders like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

Eli-lilly , Goldman-sachs , Novo-nordisk-wegovy , Lilly-zepbound , Brian-lin , Novo-nordisk , Reuters , Drug-administration , Viking-therapeutics , San-diego-based , Viking , Ozempic

Eli Lilly vies to join $1trn stock market club with Zepbound weight loss drug

Zepbound, which was recently approved for weight loss, is predicted to become the best-selling drug in history

Eli-lilly , Morgan-stanley , Weight-loss , Mounjaro , Zepbound , Organisation-eli-lilly ,